search
Back to results

Security and Efficacy of Dorilax® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low Back Pain. (Delfos)

Primary Purpose

Low Back Pain

Status
Withdrawn
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Thermal Band
Dorilax®
Placebo
Sponsored by
Ache Laboratorios Farmaceuticos S.A.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Low Back Pain

Eligibility Criteria

18 Years - 54 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Participants of both sexes aged ≥ (greater than or equal) to 18 years and ≤ (less than or equal) to 54 years;
  2. Ability to understand and consent their participation in this clinical study, expressed by signing the Informed Consent Form (ICF);
  3. Patient with acute low back pain who responds to the pain period less than or equal to 3 days;
  4. Low back pain in intensity Moderate to severe which corresponds to the severity score at least to 2 scores, evaluated by a 6 scores categoric scale;
  5. No traumatic low back pain (with no traumatic lesion for at least 7 days before randomization)
  6. Low back pain not caused or related to any clinically significant systemic disease, based on investigator evaluation.

Exclusion Criteria:

  1. Any finding of clinical observation (clinical / physical assessment) that is interpreted by the investigating physician as a risk to the participation of the research participant in the clinical study;
  2. Any laboratorial finding that the Investigator consider a risk to subject of the study;
  3. Any finding of a previous imaging examination that the investigator considers to be a risk for clinical study participation;
  4. Known hypersensitivity to the components of the medicines used during the study;
  5. Women in pregnancy or nursing period;
  6. Women who do not agree to use acceptable contraceptive methods (oral contraceptive, intravenous contraceptive, intrauterine device (IUD), hormonal implant, barrier methods, hormonal transdermal patch and tubal ligation); except for those surgically sterile (bilateral oophorectomy or hysterectomy), menopause for at least one year, and participants who report not engaging in sexual practices or non-reproductive practices;
  7. Male participants who did not agree to use acceptable methods of contraception;
  8. Subjects that has participated in clinical trial protocols in the last twelve (12) months (National Board of Health- Resolution 251 of 07 August 1997, Part III, sub-item J), unless the investigator considers that there may be a direct benefit to it;
  9. Subjects who have a relationship of kinship to second degree or any bond with the sponsor or research center employees;
  10. Any serious medical illness, at the discretion of the investigator. For example, sciatica that extends below the knee [associated with numbness, tingling, and acute and irradiated pain]) or other neurological deficits (eg, altered straight leg elevation test, abolished or diminished patellar reflex, function of the intestine and / or bladder); Orthopedic surgery history;Fibromyalgia; Diabetes mellitus; peripheral vascular disease; Osteoporosis; Gastrointestinal ulcers; Bleeding or perforation of the gastrointestinal tract; kidney disease; pulmonary edema; Cardiomyopathy; Liver disease; intrinsic defects of coagulation; Hemorrhagic diseases;
  11. Any skin lesions (eg rash, bruising, swelling, irritation, laceration, excoriation, ulceration) in the lower back.
  12. Use of β-adrenergic blocking agents, antidepressant drugs or supplements that have effects on the central nervous system or that used short- or long-acting analgesic drugs within 24 to 48 hours before randomization, respectively.
  13. History of alcohol and / or illicit drug abuse, involvement in active litigation, or worker's compensation claim involving lumbar spine deficiency, back pain for more than 28 consecutive days, or heat hypersensitivity or NSAIDs.
  14. Subjects with febrile condition (axillary temperature greater or equal to 37.8ºC)
  15. Subjects who have recently had a bacterial infection (last 90 days) that affect the vertebral column, pelvic or abdominal region; as well as participants with a history of bacterial infection that affected the spine in a chronic way;
  16. Subjects with unexplained weight loss (more than 10 kg in the last three months);
  17. Subjects who are performing some type of oral, physical or topical treatment for low back pain (eg acupuncture, local heat and yoga) and / or initiation of physiotherapy program in the last 2 months before the start of therapy. study;
  18. Diabetic subjects, controlled or not.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Other

    Arm Label

    Thermal Band plus Dorilax®

    Thermal Band plus Placebo

    Arm Description

    Outcomes

    Primary Outcome Measures

    Compare the efficacy and security of Dorilax® plus thermal banc and Placebo plus thermal band
    The relief of the pain will be evaluated using a 6 points scale. 0 = no relief; 1 = little relief; 2 = less than half of relief; 3 = more than half of relief; 4 = a lot of relief; 5 = complete relief; The first 2 hours will be evaluated at the center and the other 6 hours the subject will need to provide a diary completed hourly with the pain evaluation.

    Secondary Outcome Measures

    Evaluation of participant satisfaction with treatment
    Satisfaction of the research participant with the treatment, evaluated in the final visit (VF) by means of the visual analog scale of 100 points (EVA of 100mm, being 0mm = totally unsatisfied and 100mm = totally satisfied).

    Full Information

    First Posted
    April 16, 2018
    Last Updated
    July 3, 2019
    Sponsor
    Ache Laboratorios Farmaceuticos S.A.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03508167
    Brief Title
    Security and Efficacy of Dorilax® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low Back Pain.
    Acronym
    Delfos
    Official Title
    National, Phase III, Monocentric, Randomized, Double-blind, Controlled, Parallel, to Evaluate the Security and Efficacy of Dorilax® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low Back Pain.
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2019
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Study design will be reformulated
    Study Start Date
    January 2020 (Anticipated)
    Primary Completion Date
    October 2020 (Anticipated)
    Study Completion Date
    November 2020 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Ache Laboratorios Farmaceuticos S.A.

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    National clinical trial, phase III, monocentric, randomized, double-blind, controlled, parallel, study of superiority, in which two hundred and thirty four (234) participants of both sexes, aged equal or more than 18 years and equal or less than 54 years, will be randomly allocated in one of two treatment groups. The first group will use Dorilax® plus thermal band and the second group will use thermal band plus placebo. The results will show the efficacy and security of Dorilax® and compare the efficiency of Dorilax® and thermal band.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Low Back Pain

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigator
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Thermal Band plus Dorilax®
    Arm Type
    Experimental
    Arm Title
    Thermal Band plus Placebo
    Arm Type
    Other
    Intervention Type
    Device
    Intervention Name(s)
    Thermal Band
    Intervention Description
    Thermal Band used 8 hours per day
    Intervention Type
    Drug
    Intervention Name(s)
    Dorilax®
    Intervention Description
    2 tablets, orally. In case of moderate pain, another 2 tablets could be administered, respecting the interval of 8 hours between the administrations. Maximum dosage per day: 6 tablets.
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Intervention Description
    2 tablets, orally. In case of moderate pain, another 2 tablets could be administered, respecting the interval of 8 hours between the administrations. Maximum dosage per day: 6 tablets.
    Primary Outcome Measure Information:
    Title
    Compare the efficacy and security of Dorilax® plus thermal banc and Placebo plus thermal band
    Description
    The relief of the pain will be evaluated using a 6 points scale. 0 = no relief; 1 = little relief; 2 = less than half of relief; 3 = more than half of relief; 4 = a lot of relief; 5 = complete relief; The first 2 hours will be evaluated at the center and the other 6 hours the subject will need to provide a diary completed hourly with the pain evaluation.
    Time Frame
    8 hours
    Secondary Outcome Measure Information:
    Title
    Evaluation of participant satisfaction with treatment
    Description
    Satisfaction of the research participant with the treatment, evaluated in the final visit (VF) by means of the visual analog scale of 100 points (EVA of 100mm, being 0mm = totally unsatisfied and 100mm = totally satisfied).
    Time Frame
    72 (+24) hours

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    54 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Participants of both sexes aged ≥ (greater than or equal) to 18 years and ≤ (less than or equal) to 54 years; Ability to understand and consent their participation in this clinical study, expressed by signing the Informed Consent Form (ICF); Patient with acute low back pain who responds to the pain period less than or equal to 3 days; Low back pain in intensity Moderate to severe which corresponds to the severity score at least to 2 scores, evaluated by a 6 scores categoric scale; No traumatic low back pain (with no traumatic lesion for at least 7 days before randomization) Low back pain not caused or related to any clinically significant systemic disease, based on investigator evaluation. Exclusion Criteria: Any finding of clinical observation (clinical / physical assessment) that is interpreted by the investigating physician as a risk to the participation of the research participant in the clinical study; Any laboratorial finding that the Investigator consider a risk to subject of the study; Any finding of a previous imaging examination that the investigator considers to be a risk for clinical study participation; Known hypersensitivity to the components of the medicines used during the study; Women in pregnancy or nursing period; Women who do not agree to use acceptable contraceptive methods (oral contraceptive, intravenous contraceptive, intrauterine device (IUD), hormonal implant, barrier methods, hormonal transdermal patch and tubal ligation); except for those surgically sterile (bilateral oophorectomy or hysterectomy), menopause for at least one year, and participants who report not engaging in sexual practices or non-reproductive practices; Male participants who did not agree to use acceptable methods of contraception; Subjects that has participated in clinical trial protocols in the last twelve (12) months (National Board of Health- Resolution 251 of 07 August 1997, Part III, sub-item J), unless the investigator considers that there may be a direct benefit to it; Subjects who have a relationship of kinship to second degree or any bond with the sponsor or research center employees; Any serious medical illness, at the discretion of the investigator. For example, sciatica that extends below the knee [associated with numbness, tingling, and acute and irradiated pain]) or other neurological deficits (eg, altered straight leg elevation test, abolished or diminished patellar reflex, function of the intestine and / or bladder); Orthopedic surgery history;Fibromyalgia; Diabetes mellitus; peripheral vascular disease; Osteoporosis; Gastrointestinal ulcers; Bleeding or perforation of the gastrointestinal tract; kidney disease; pulmonary edema; Cardiomyopathy; Liver disease; intrinsic defects of coagulation; Hemorrhagic diseases; Any skin lesions (eg rash, bruising, swelling, irritation, laceration, excoriation, ulceration) in the lower back. Use of β-adrenergic blocking agents, antidepressant drugs or supplements that have effects on the central nervous system or that used short- or long-acting analgesic drugs within 24 to 48 hours before randomization, respectively. History of alcohol and / or illicit drug abuse, involvement in active litigation, or worker's compensation claim involving lumbar spine deficiency, back pain for more than 28 consecutive days, or heat hypersensitivity or NSAIDs. Subjects with febrile condition (axillary temperature greater or equal to 37.8ºC) Subjects who have recently had a bacterial infection (last 90 days) that affect the vertebral column, pelvic or abdominal region; as well as participants with a history of bacterial infection that affected the spine in a chronic way; Subjects with unexplained weight loss (more than 10 kg in the last three months); Subjects who are performing some type of oral, physical or topical treatment for low back pain (eg acupuncture, local heat and yoga) and / or initiation of physiotherapy program in the last 2 months before the start of therapy. study; Diabetic subjects, controlled or not.

    12. IPD Sharing Statement

    Learn more about this trial

    Security and Efficacy of Dorilax® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low Back Pain.

    We'll reach out to this number within 24 hrs